GlycoT Therapeutics licenses glycoengineering tech to Daiichi Sankyo

By The Science Advisory Board staff writers

September 14, 2020 -- GlycoT Therapeutics has signed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo.

The agreement grants Daiichi Sankyo worldwide and nonexclusive rights to intellectual property that GlycoT currently licenses from the University of Maryland, Baltimore and University of Maryland, College Park. The deal includes an undisclosed upfront payment, annual fees, and royalties on sales of GlycoT.

The enzymatic glycoengineering technology platform allows scientists to precisely change and modify the sugars on monoclonal antibodies. Daiichi Sankyo plans to use the technology in the development of new drug candidates.

The technology was originally developed by Lai-Xi Wang, PhD, founder and president of GlycoT Therapeutics and professor in the department of chemistry and biochemistry at the University of Maryland, College Park.

Synaffix, ADC Therapeutics collaborate on antibody drug conjugates
Synaffix and ADC Therapeutics have expanded an existing collaboration to explore additional applications of Synaffix's site-specific conjugation technologies.
Pioneering technology stabilizes vaccines at all temperatures
Scientists have identified a new method called ensilication to prevent warmed-up vaccines from degrading. By coating proteins in a silica shell, the structures...
Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...
Researchers bait viruses with chemically designed structures
A new therapeutic approach for suppressing seasonal influenza that involves synthetic phage shells that interfere with pathogen adhesion is immediately...
Could more sugar-based drugs be on the way?
Researchers from Denmark have developed a new technique to characterize complex sugar molecules in exquisite detail never before achieved, according to...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter